Non-pegylated liposomal doxorubicin (Myocet)
Jump to navigation
Jump to search
General information
Class/mechanism: A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity.
Diseases for which it is used
History of changes in EMA indication
- 2000-07-13: Initial marketing authorization as Myocet.
- Uncertain date: Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.
Also known as
- Generic names: liposome-encapsulated doxorubicin citrate, NPLD
- Brand name: Myocet